Clinical endocrinological evaluation of the gonadal axis (testosterone, LH and FSH) in prostate cancer patients switched from a GnRH antagonist to a LHRH agonist.

To investigate the levels of testosterone, luteinizing hormone (LH), follicle-stimulating hormone (FSH), and prostate-specific antigen (PSA) in prostate cancer patients before and after the switch from degarelix to leuprolide treatments.

We enrolled 40 treatment-naïve prostate cancer patients who were treated initially with degarelix and were later switched to leuprolide The subjects were divided into three groups depending on when they were switched to leuprolide: the 3-month group (3m; switched after 84 days, n=10), the 2-month group (2m; 56 days, n=10), and the 1-month group (1m; 28 days, n=20) Patient symptoms and hormone levels were measured after switching therapy The castration level was defined as a serum testosterone level ≤50 ng/dl

Thirty-nine subjects (97 5%) achieved castration levels of testosterone (11±5 8 ng/dl) 2 weeks after degarelix was first administered, and the characteristics of these patients were investigated Testosterone levels increased and exceeded the castration level in one subject each of the 3m (142 ng/dl), 2m (72 ng/dl), and 1m groups (63 ng/dl) All subjects achieved the castration level by day 5 In contrast to testosterone levels, the LH and FSH surge on day 2 was significantly higher in the 1m group than in the other groups The clinical symptoms were not exacerbated before or after switching in any patients

A testosterone surge was observed in 8 3 % of the study patients; however, it was very short-lived and mild LH and FSH levels were significantly higher 1 month after administration compared with 2 or 3 months after degarelix administration

Basic and clinical andrology 2015 Jul 03*** epublish ***

Yoshiyuki Miyazawa, Haruo Kato, Seiji Arai, Yosuke Furuya, Yoshitaka Sekine, Masashi Nomura, Hidekazu Koike, Hiroshi Matsui, Yasuhiro Shibata, Kazuto Ito, Kazuhiro Suzuki

Department of Urology, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi 371-8511 Gunma, Japan , Department of Urology, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi 371-8511 Gunma, Japan , Department of Urology, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi 371-8511 Gunma, Japan , Department of Urology, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi 371-8511 Gunma, Japan , Department of Urology, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi 371-8511 Gunma, Japan , Department of Urology, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi 371-8511 Gunma, Japan , Department of Urology, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi 371-8511 Gunma, Japan , Department of Urology, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi 371-8511 Gunma, Japan , Department of Urology, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi 371-8511 Gunma, Japan , Department of Urology, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi 371-8511 Gunma, Japan , Department of Urology, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi 371-8511 Gunma, Japan

PubMed